Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/24/2026 | $137.00 | Outperform | RBC Capital Mkts |
| 1/28/2026 | $144.00 | Hold → Buy | HSBC Securities |
| 1/14/2026 | $131.00 | Buy → Hold | TD Cowen |
| 12/11/2025 | $176.00 | Buy | UBS |
| 7/14/2025 | Mkt Outperform → Mkt Perform | Citizens JMP | |
| 7/9/2025 | $142.00 | Buy → Hold | HSBC Securities |
| 6/30/2025 | $150.00 | Overweight | Piper Sandler |
| 5/14/2025 | $150.00 | Equal-Weight → Overweight | Morgan Stanley |
Japan Post Insurance Co., Ltd. ("Japan Post Insurance"), Hoken Minaoshi Hompo Group, Inc. ("Hoken Minaoshi Hompo Group" or the "Company"), a leading insurance distributor in Japan, and KKR, a leading global investment firm, today announced that Japan Post Insurance has acquired a minority stake in Hoken Minaoshi Hompo Group. This follows the acquisition of Hoken Minaoshi Hompo Group in 2025 by funds managed by KKR, which remains the majority shareholder. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330133249/en/ Japan Post Insurance's investment will further enable Hoken Minaoshi Hompo Group to accelerate its growth strateg
KKR and its investors achieve 15x return 100% of CoolIT employees receive significant payouts KKR, a leading global investment firm, today announced that it has entered into a definitive agreement to sell CoolIT Systems ("CoolIT" or "the Company"), a global leader in liquid data center cooling, to Ecolab in a transaction valued at $4.75 billion. The sale will represent one of KKR's largest recent realizations, generating approximately 15x the original equity invested, inclusive of distributions. At the close of the transaction, all CoolIT employees will receive a substantial cash payout on their ownership in the Company. Mubadala Investment Company ("Mubadala") also served as a co-inves
KKR today announced income from monetization activity in excess of $700 million with respect to the period from January 1, 2026 through March 23, 2026 based on information available as of today. The quarter-to-date monetization activity is made up of approximately 90% realized performance income and approximately 10% realized investment income. The quarter-to-date monetization activity is driven by a combination of public secondary sales and strategic transactions, as well as dividends and interest income. The estimate disclosed above is not intended to predict or represent total realized performance income, total realized investment income or total revenues for the full quarter ending
SCHEDULE 13G/A - KKR & Co. Inc. (0001404912) (Subject)
DEFA14A - KKR & Co. Inc. (0001404912) (Filer)
DEFA14A - KKR & Co. Inc. (0001404912) (Filer)
4 - KKR & Co. Inc. (0001404912) (Issuer)
4 - KKR & Co. Inc. (0001404912) (Issuer)
4 - KKR & Co. Inc. (0001404912) (Issuer)
RBC Capital Mkts initiated coverage of KKR with a rating of Outperform and set a new price target of $137.00
HSBC Securities upgraded KKR from Hold to Buy and set a new price target of $144.00
TD Cowen downgraded KKR from Buy to Hold and set a new price target of $131.00
4 - KKR & Co. Inc. (0001404912) (Reporting)
4 - KKR & Co. Inc. (0001404912) (Issuer)
4 - KKR & Co. Inc. (0001404912) (Reporting)
Global investment firm KKR today announced the completion of an additional investment in Sylvan, a world-leading fungal biotechnology company (the "Company"), through funds managed by KKR with participation from new investors and a follow-on investment from existing investor, Novo Holdings, which increased its ownership stake in the Company as part of this round. Following the investment, KKR remains the majority investor in Sylvan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260120305013/en/ Founded in 1932, Sylvan is a world-leading mushroom spawn and fungal biotechnology company. The company seeks to harness the potential
Peak Reinsurance Company Limited ("Peak Re" or the "Company") and KKR, a leading global investment firm, today announced that funds managed by KKR and Quadrantis Capital have entered into definitive agreements to acquire minority stakes in Peak Re via Peak Reinsurance Holdings Limited. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251020924186/en/ Upon completion, KKR and Quadrantis Capital are expected to hold approximately 11.27% and approximately 1.80% of Peak Re's issued share capital, respectively, with the remaining approximately 86.71% continuing to be held by the majority shareholder, Fosun International Limited. Pruden
KKR & Co. Inc. (NYSE:KKR) today announced that Craig Arnold has been appointed to the Board of Directors effective September 23, 2025. His appointment will bring the number of independent directors to eleven out of a total of fifteen Board seats. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250924641078/en/Craig Arnold Mr. Arnold is the former Chairman and Chief Executive Officer of Eaton Corporation, a global intelligent power management company. KKR's other Board members are: Henry Kravis (Co-Founder and Co-Executive Chairman of KKR), George Roberts (Co-Founder and Co-Executive Chairman of KKR), Joseph Bae (Co-Executive Of
Japan Post Insurance Co., Ltd. ("Japan Post Insurance"), Hoken Minaoshi Hompo Group, Inc. ("Hoken Minaoshi Hompo Group" or the "Company"), a leading insurance distributor in Japan, and KKR, a leading global investment firm, today announced that Japan Post Insurance has acquired a minority stake in Hoken Minaoshi Hompo Group. This follows the acquisition of Hoken Minaoshi Hompo Group in 2025 by funds managed by KKR, which remains the majority shareholder. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330133249/en/ Japan Post Insurance's investment will further enable Hoken Minaoshi Hompo Group to accelerate its growth strateg
KKR today announced income from monetization activity in excess of $700 million with respect to the period from January 1, 2026 through March 23, 2026 based on information available as of today. The quarter-to-date monetization activity is made up of approximately 90% realized performance income and approximately 10% realized investment income. The quarter-to-date monetization activity is driven by a combination of public secondary sales and strategic transactions, as well as dividends and interest income. The estimate disclosed above is not intended to predict or represent total realized performance income, total realized investment income or total revenues for the full quarter ending
– Enbumyst™ Is the First and Only FDA-Approved Nasal Spray Loop Diuretic for Edema Associated with Congestive Heart Failure, Expected to Leverage Esperion's Established Cardiovascular Commercial Infrastructure, Synergistically Expand Product Portfolio and Accelerate Double-Digit Revenue Growth – – Upfront Cash Payment of $75 Million, Royalties on Worldwide Enbumyst Sales and Up to $180 Million in Potential Milestone Payments Tied to Certain Commercial and Regulatory Achievements – – Esperion to Host Conference Call on Tuesday, March 3, 2026 at 8:00 am ET – ANN ARBOR, Mich. and HENDERSON, Nev., March 03, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) and Corstasis Therapeutics Inc., a p
SC 13G/A - KKR & Co. Inc. (0001404912) (Subject)
SC 13G/A - KKR & Co. Inc. (0001404912) (Subject)
SC 13G/A - KKR & Co. Inc. (0001404912) (Subject)